| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | Vorinostat | FIMM | pan-cancer | AAC | -0.05 | 0.8 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |